Key result
MicroRNAs show promise as therapeutic targets to treat cardiac hypertrophy.
Answers are grounded in this paper and cite their sources.
Like other organs, the heart undergoes normal adaptive remodeling, such as cardiac hypertrophy, with age. This remodeling, however, is intensified under stress and pathological conditions. Cardiac remodeling could be beneficial for a short period of time, to maintain a normal cardiac output in times of need; however, chronic cardiac hypertrophy may lead to heart failure and death. MicroRNAs (miRNAs) are known to have a role in the regulation of cardiac hypertrophy. This paper reviews recent advances in the field of miRNAs and cardiac hypertrophy, highlighting the latest findings for targeted genes and involved signaling pathways. By targeting pro-hypertrophic genes and signaling pathways, some of these miRNAs alleviate cardiac hypertrophy, while others enhance it. Therefore, miRNAs represent very promising potential pharmacotherapeutic targets for the management and treatment of cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Wehbe et al. (2019) conducted a review in Cardiac hypertrophy. MicroRNAs (miRNAs) was evaluated. MicroRNAs represent promising potential pharmacotherapeutic targets for the management and treatment of cardiac hypertrophy by targeting pro-hypertrophic genes and signaling pathways.
Synapse has enriched 10 related papers. Consider them for comparative context: